Lihe Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lihe Lu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Jianyun Yan
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China; Guangdong Provincial Key Laboratory of Cardiac Function and Microcirculation, Guangdong Provincial Biomedical Engineering Technology Research Center for Cardiovascular Disease, Guangzhou, 510280, China
7 shared publications - Yuanzhi Ye
Department of Cardiology, Laboratory of Heart Center, Heart Center Zhujiang Hospital, Southern Medical University Guangzhou China
7 shared publications - An Chen
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China. (Q.D., X.Z., L.F., A.C., Z.L., Y.Y., J.Z., X.L., Y.L., J.Y.)
5 shared publications - Qingchun Liang
Department of Anesthesiology, The Third Affiliated Hospital, Southern Medical University, Guangzhou, China
5 shared publications - Zirong Lan
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China. (Q.D., X.Z., L.F., A.C., Z.L., Y.Y., J.Z., X.L., Y.L., J.Y.)
5 shared publications - Liyun Feng
Department of Cardiology, Laboratory of Heart Center, Heart Center, Zhujiang Hospital, Southern Medical University, China. (Q.D., X.Z., L.F., A.C., Z.L., Y.Y., J.Z., X.L., Y.L., J.Y.)
4 shared publications
Latest Publications
- 4 September 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease
BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging effect on vascular smooth muscle cells. However, whether NAMPT is involved in the regulation of vascular calcification remains unclear. METHODS: ELISA, immunofluorescence, and Western blot were used to detect NAMPT levels in human blood and tissues. Alizarin red staining, calcium content assay, and microcomputed tomography were used to investigate the role of NAMPT in vascular calcification. Gene expression analysis and coimmunoprecipitation were performed to elucidate the underlying mechanism. RESULTS: ELISA, immunofluorescence, and Western blot showed that NAMPT levels were increased in the blood of patients with chronic kidney disease and human calcified arterial tissues. Alizarin red staining and calcium content assay revealed that pharmacological inhibition or knockdown of NAMPT exacerbated vascular smooth muscle cell calcification, whereas overexpression of NAMPT reduced mineral deposition under osteogenic conditions. Similarly, ex vivo studies revealed that NAMPT inhibited calcification of rat and human arterial rings. Moreover, administration of NAMPT inhibitor FK866 promoted aortic calcification of chronic kidney disease rats, and smooth muscle cell–specific NAMPT knockout mice exhibited aggravated aortic calcification. Furthermore, pharmacological inhibition and knockdown of SIRT1 (sirtuin 1) abrogated the inhibitory effect of NAMPT on vascular calcification. In addition, smooth muscle cell–specific SIRT1 deficiency abrogated the protective effect of recombinant NAMPT on mouse aortic calcification. Coimmunoprecipitation and immunofluorescence assay further revealed that NAMPT inhibited the acetylation of NICD (Notch intracellular domain) and reduced the expression of HES1 (hairy and enhancer of split-1) in a SIRT1-dependent pathway. CONCLUSIONS: Our study unveils that NAMPT could serve as a novel endogenous inhibitor of vascular calcification via modulation of SIRT1-mediated deacetylation of NICD.
- 4 September 2025
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
NAMPT Is A Novel Inhibitor of Vascular Calcification in Chronic Kidney Disease
BACKGROUND: Vascular calcification is very common in patients with chronic kidney disease and contributes to the increased risk of cardiovascular events. NAMPT (nicotinamide phosphoribosyltransferase), the rate-limiting enzyme in the salvage pathway of nicotinamide adenine dinucleotide, has been shown to exert an antiaging effect on vascular smooth muscle cells. However, whether NAMPT is involved in the regulation of vascular calcification remains unclear. METHODS: ELISA, immunofluorescence, and Western blot were used to detect NAMPT levels in human blood and tissues. Alizarin red staining, calcium content assay, and microcomputed tomography were used to investigate the role of NAMPT in vascular calcification. Gene expression analysis and coimmunoprecipitation were performed to elucidate the underlying mechanism. RESULTS: ELISA, immunofluorescence, and Western blot showed that NAMPT levels were increased in the blood of patients with chronic kidney disease and human calcified arterial tissues. Alizarin red staining and calcium content assay revealed that pharmacological inhibition or knockdown of NAMPT exacerbated vascular smooth muscle cell calcification, whereas overexpression of NAMPT reduced mineral deposition under osteogenic conditions. Similarly, ex vivo studies revealed that NAMPT inhibited calcification of rat and human arterial rings. Moreover, administration of NAMPT inhibitor FK866 promoted aortic calcification of chronic kidney disease rats, and smooth muscle cell–specific NAMPT knockout mice exhibited aggravated aortic calcification. Furthermore, pharmacological inhibition and knockdown of SIRT1 (sirtuin 1) abrogated the inhibitory effect of NAMPT on vascular calcification. In addition, smooth muscle cell–specific SIRT1 deficiency abrogated the protective effect of recombinant NAMPT on mouse aortic calcification. Coimmunoprecipitation and immunofluorescence assay further revealed that NAMPT inhibited the acetylation of NICD (Notch intracellular domain) and reduced the expression of HES1 (hairy and enhancer of split-1) in a SIRT1-dependent pathway. CONCLUSIONS: Our study unveils that NAMPT could serve as a novel endogenous inhibitor of vascular calcification via modulation of SIRT1-mediated deacetylation of NICD.
- 27 June 2025
- Published by Wolters Kluwer Health in Circulation Research
E3 Ubiquitin Ligase TRIM16-Mediated K63-linked Ubiquitination of DAB2 Enhances Integrin β1 Endocytosis to Facilitate Vascular Calcification
BACKGROUND: Vascular calcification is highly prevalent in patients with chronic kidney disease (CKD), and the underlying mechanisms remain elusive. Several studies have indicated an important role of protein ubiquitination in vascular calcification. However, the role of E3 ubiquitin ligases in vascular calcification remains poorly understood. METHODS: Calcification of vascular smooth muscle cells (VSMCs) was induced by high phosphate. CKD mouse model was induced by an adenine diet, and CKD rat model was established using 5/6 nephrectomy method. Adenovirus, siRNA, adeno-associated virus, and smooth muscle cell–specific TRIM16 (tripartite motif 16) knockout mice were used to investigate the role of TRIM16 in vascular calcification. Immunoprecipitation–mass spectrometry, and ubiquitination assay were used to dissect how TRIM16 regulates vascular calcification. RESULTS: Bioinformatic analysis suggested that E3 ubiquitin TRIM16 could be a key modulator of vascular calcification. TRIM16 expression was increased during vascular calcification. Overexpression of TRIM16 exacerbated VSMC calcification and aortic calcification of CKD rats. By contrast, the knockdown of TRIM16 alleviated VSMC calcification and aortic calcification in CKD rats. Moreover, the deletion of TRIM16 inhibited VSMC calcification and aortic calcification in VitD3-overloaded mice and CKD mice. Mechanistically, immunoprecipitation–mass spectrometry revealed that DAB2 (disabled homolog 2) was the potential downstream target of TRIM16. Coimmunoprecipitation showed that the SPRY domain of TRIM16 interacted with the proline-rich domain of DAB2. Moreover, ubiquitination assay revealed that the SPRY domain of TRIM16 is required for TRIM16-mediated K63-linked ubiquitination of DAB2 at K656 residue. Of note, the knockdown of DAB2 inhibited TRIM16-induced VSMC calcification. Furthermore, knockdown of DAB2 antagonized endocytosis of integrin β1 and subsequent activation of FAK (focal adhesion kinase)-STAT3 (signal transduction and transcriptional activation factor 3) signaling induced by overexpression of TRIM16. CONCLUSIONS: Our study for the first time demonstrates that E3 ubiquitin ligase TRIM16 catalyzes K63-ubiquitination of the endocytic adaptor DAB2, leading to endocytosis of integrin β1 and activation of FAK-STAT3 signaling, and subsequently exacerbates vascular calcification, suggesting that TRIM16-DAB2 axis is a promising therapeutic target for vascular calcification.
- 27 June 2025
- Published by Wolters Kluwer Health in Circulation Research
E3 Ubiquitin Ligase TRIM16-Mediated K63-linked Ubiquitination of DAB2 Enhances Integrin β1 Endocytosis to Facilitate Vascular Calcification
BACKGROUND: Vascular calcification is highly prevalent in patients with chronic kidney disease (CKD), and the underlying mechanisms remain elusive. Several studies have indicated an important role of protein ubiquitination in vascular calcification. However, the role of E3 ubiquitin ligases in vascular calcification remains poorly understood. METHODS: Calcification of vascular smooth muscle cells (VSMCs) was induced by high phosphate. CKD mouse model was induced by an adenine diet, and CKD rat model was established using 5/6 nephrectomy method. Adenovirus, siRNA, adeno-associated virus, and smooth muscle cell–specific TRIM16 (tripartite motif 16) knockout mice were used to investigate the role of TRIM16 in vascular calcification. Immunoprecipitation–mass spectrometry, and ubiquitination assay were used to dissect how TRIM16 regulates vascular calcification. RESULTS: Bioinformatic analysis suggested that E3 ubiquitin TRIM16 could be a key modulator of vascular calcification. TRIM16 expression was increased during vascular calcification. Overexpression of TRIM16 exacerbated VSMC calcification and aortic calcification of CKD rats. By contrast, the knockdown of TRIM16 alleviated VSMC calcification and aortic calcification in CKD rats. Moreover, the deletion of TRIM16 inhibited VSMC calcification and aortic calcification in VitD3-overloaded mice and CKD mice. Mechanistically, immunoprecipitation–mass spectrometry revealed that DAB2 (disabled homolog 2) was the potential downstream target of TRIM16. Coimmunoprecipitation showed that the SPRY domain of TRIM16 interacted with the proline-rich domain of DAB2. Moreover, ubiquitination assay revealed that the SPRY domain of TRIM16 is required for TRIM16-mediated K63-linked ubiquitination of DAB2 at K656 residue. Of note, the knockdown of DAB2 inhibited TRIM16-induced VSMC calcification. Furthermore, knockdown of DAB2 antagonized endocytosis of integrin β1 and subsequent activation of FAK (focal adhesion kinase)-STAT3 (signal transduction and transcriptional activation factor 3) signaling induced by overexpression of TRIM16. CONCLUSIONS: Our study for the first time demonstrates that E3 ubiquitin ligase TRIM16 catalyzes K63-ubiquitination of the endocytic adaptor DAB2, leading to endocytosis of integrin β1 and activation of FAK-STAT3 signaling, and subsequently exacerbates vascular calcification, suggesting that TRIM16-DAB2 axis is a promising therapeutic target for vascular calcification.
- 28 May 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (11) , e70677
GDF11 Alleviates Vascular Calcification in VitD 3 ‐Overloaded Mice Through Inhibition of Inflammatory NF‐κB Signal
Vascular calcification, an age‐associated disorder, is a highly regulated biological process similar to bone formation. Growth differentiation factor 11 (GDF11), a secreted member of the transforming growth factor beta (TGF‐β) superfamily, has been shown to act as an anti‐aging factor in the brain, heart, skin, and skeletal muscle. Nevertheless, whether GDF11 affects vascular calcification and the underlying mechanisms remain unclear. In the present study, beta‐glycerophosphate and calcium chloride‐induced calcification of vascular smooth muscle cells (VSMCs) and a VitD 3 ‐overloaded mouse model were used to investigate the role of GDF11 in vascular calcification. Our results revealed that the knockdown of GDF11 by siRNA promoted the calcification of rat VSMCs, whereas GDF11 treatment significantly reduced the calcification of human and rat VSMCs in vitro, as detected by alizarin red staining and calcium content assay. Similarly, GDF11 treatment reduced the expression of bone‐related molecules including Runt‐related transcription factor 2 (Runx2) and bone morphogenetic protein‐2 (BMP2). Furthermore, ex vivo and in vivo studies confirmed the inhibitory effect of GDF11 on vascular calcification. Mechanistically, GDF11 treatment reduced the levels of NF‐κB signaling molecules including NLRP3, phosphorylated p65, IL‐6, and IL‐1β in VSMCs. Additionally, GDF11 siRNA‐induced VSMC calcification was repressed by NF‐κB inhibitor PDTC treatment. Taken together, these findings suggest that GDF11 alleviates vascular calcification through inhibiting the NF‐κB signal. Modulation of GDF11 may represent a therapeutic strategy for vascular calcification.
- 28 May 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (11) , e70677
GDF11 Alleviates Vascular Calcification in VitD 3 ‐Overloaded Mice Through Inhibition of Inflammatory NF‐κB Signal
Vascular calcification, an age‐associated disorder, is a highly regulated biological process similar to bone formation. Growth differentiation factor 11 (GDF11), a secreted member of the transforming growth factor beta (TGF‐β) superfamily, has been shown to act as an anti‐aging factor in the brain, heart, skin, and skeletal muscle. Nevertheless, whether GDF11 affects vascular calcification and the underlying mechanisms remain unclear. In the present study, beta‐glycerophosphate and calcium chloride‐induced calcification of vascular smooth muscle cells (VSMCs) and a VitD 3 ‐overloaded mouse model were used to investigate the role of GDF11 in vascular calcification. Our results revealed that the knockdown of GDF11 by siRNA promoted the calcification of rat VSMCs, whereas GDF11 treatment significantly reduced the calcification of human and rat VSMCs in vitro, as detected by alizarin red staining and calcium content assay. Similarly, GDF11 treatment reduced the expression of bone‐related molecules including Runt‐related transcription factor 2 (Runx2) and bone morphogenetic protein‐2 (BMP2). Furthermore, ex vivo and in vivo studies confirmed the inhibitory effect of GDF11 on vascular calcification. Mechanistically, GDF11 treatment reduced the levels of NF‐κB signaling molecules including NLRP3, phosphorylated p65, IL‐6, and IL‐1β in VSMCs. Additionally, GDF11 siRNA‐induced VSMC calcification was repressed by NF‐κB inhibitor PDTC treatment. Taken together, these findings suggest that GDF11 alleviates vascular calcification through inhibiting the NF‐κB signal. Modulation of GDF11 may represent a therapeutic strategy for vascular calcification.
- 7 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70530
STING Facilitates Vascular Calcification via p‐STAT1/NLRP3 Signal
Vascular calcification is an independent predictor of cardiovascular mortality in patients with chronic kidney disease (CKD), yet no approved treatment exists. The cGAS‐STING signaling participates in various cardiovascular diseases. Notably, DNA damage, an important regulator of vascular calcification, activates the cGAS‐STING signaling. However, it remains poorly understood whether STING regulates vascular calcification under CKD conditions. In the current study, we showed that the expression of STING was elevated during vascular calcification. STING knockdown or pharmacological inhibition decreased calcium deposits in vascular smooth muscle cells and human arterial rings, while its activation exacerbated calcification. Furthermore, STING knockout mice exhibited reduced aortic calcification. RNA sequencing analysis suggested that the STAT1 signaling pathway may mediate STING‐induced vascular calcification. STING knockdown decreased phosphorylated STAT1 (p‐STAT1) levels, and inhibition of p‐STAT1 mitigated STING‐induced calcification in VSMCs and human arterial tissues. Additionally, STING knockdown downregulated NLRP3 expression, and inhibiting NLRP3 further attenuated STING‐induced VSMC calcification, indicating STING accelerates vascular calcification via NLRP3 activation. Altogether, our study highlights the STING/p‐STAT1/NLRP3 signaling axis as a key mediator in vascular calcification, suggesting that targeting STING may represent a promising therapeutic approach for vascular calcification in CKD patients.
- 7 April 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (7) , e70530
STING Facilitates Vascular Calcification via p‐STAT1/NLRP3 Signal
Vascular calcification is an independent predictor of cardiovascular mortality in patients with chronic kidney disease (CKD), yet no approved treatment exists. The cGAS‐STING signaling participates in various cardiovascular diseases. Notably, DNA damage, an important regulator of vascular calcification, activates the cGAS‐STING signaling. However, it remains poorly understood whether STING regulates vascular calcification under CKD conditions. In the current study, we showed that the expression of STING was elevated during vascular calcification. STING knockdown or pharmacological inhibition decreased calcium deposits in vascular smooth muscle cells and human arterial rings, while its activation exacerbated calcification. Furthermore, STING knockout mice exhibited reduced aortic calcification. RNA sequencing analysis suggested that the STAT1 signaling pathway may mediate STING‐induced vascular calcification. STING knockdown decreased phosphorylated STAT1 (p‐STAT1) levels, and inhibition of p‐STAT1 mitigated STING‐induced calcification in VSMCs and human arterial tissues. Additionally, STING knockdown downregulated NLRP3 expression, and inhibiting NLRP3 further attenuated STING‐induced VSMC calcification, indicating STING accelerates vascular calcification via NLRP3 activation. Altogether, our study highlights the STING/p‐STAT1/NLRP3 signaling axis as a key mediator in vascular calcification, suggesting that targeting STING may represent a promising therapeutic approach for vascular calcification in CKD patients.
- 14 March 2025
- Published by Wiley in The Journal of Pathology
- Vol. 266 (1) , 109-123
Thrombospondin‐1 binds to integrin β3 to inhibit vascular calcification through suppression of NF‐κB pathway
Vascular calcification is an important risk factor related to all‐cause mortality of cardiovascular events in patients with chronic kidney disease (CKD). Vascular extracellular matrix (ECM) proteins have been demonstrated to regulate vascular calcification. ECM protein thrombospondin 1 (THBS1/TSP‐1) plays a critical role in the regulation of vascular diseases. However, whether THBS1 is involved in vascular calcification in CKD patients remains unclear. In this study, RNA sequencing datasets from the Gene Expression Omnibus (GEO) database GSE146638 showed that THBS1 was upregulated in the aortas of CKD rats. Enzyme‐linked immunosorbent assay (elisa) revealed that serum THBS1 levels were increased in CKD patients with thoracic calcification. Western blotting and immunofluorescence analysis showed that THBS1 expression was increased in calcified vascular smooth muscle cells (VSMCs) and arteries. THBS1 knockdown exacerbated rat VSMC calcification induced by high phosphorus and calcium, as shown by Alizarin red staining and calcium content assays. Conversely, THBS1 overexpression attenuated VSMC calcification and abdominal aortic calcification in rats with CKD. Moreover, addition of recombinant THBS1 protein inhibited calcification of VSMCS and human arterial rings. Smooth muscle cell‐specific knockout of THBS1 mice treated with vitamin D3 displayed aggravated aortic calcification. Mechanistically, the protein–protein interaction database STRING (http://string-db.org/) analysis and coimmunoprecipitation assays revealed THBS1 bound to integrin β3. Reduction of integrin β3 levels abrogated the protective effect of THBS1 on vascular calcification. RNA‐seq analysis revealed that THBS1 overexpression modulated the nuclear factor‐kappa B (NF‐κB) signaling pathway. Of note, the inhibitory effect of THBS1 overexpression on the NF‐κB signal was abolished by knockdown of integrin β3. In conclusion, THBS1 interacts with integrin β3 to inhibit vascular calcification through suppression of NF‐κB signal, suggesting a promising therapeutic target for vascular calcification in CKD. © 2025 The Pathological Society of Great Britain and Ireland.
- 14 March 2025
- Published by Wiley in The Journal of Pathology
- Vol. 266 (1) , 109-123
Thrombospondin‐1 binds to integrin β3 to inhibit vascular calcification through suppression of NF‐κB pathway
Vascular calcification is an important risk factor related to all‐cause mortality of cardiovascular events in patients with chronic kidney disease (CKD). Vascular extracellular matrix (ECM) proteins have been demonstrated to regulate vascular calcification. ECM protein thrombospondin 1 (THBS1/TSP‐1) plays a critical role in the regulation of vascular diseases. However, whether THBS1 is involved in vascular calcification in CKD patients remains unclear. In this study, RNA sequencing datasets from the Gene Expression Omnibus (GEO) database GSE146638 showed that THBS1 was upregulated in the aortas of CKD rats. Enzyme‐linked immunosorbent assay (elisa) revealed that serum THBS1 levels were increased in CKD patients with thoracic calcification. Western blotting and immunofluorescence analysis showed that THBS1 expression was increased in calcified vascular smooth muscle cells (VSMCs) and arteries. THBS1 knockdown exacerbated rat VSMC calcification induced by high phosphorus and calcium, as shown by Alizarin red staining and calcium content assays. Conversely, THBS1 overexpression attenuated VSMC calcification and abdominal aortic calcification in rats with CKD. Moreover, addition of recombinant THBS1 protein inhibited calcification of VSMCS and human arterial rings. Smooth muscle cell‐specific knockout of THBS1 mice treated with vitamin D3 displayed aggravated aortic calcification. Mechanistically, the protein–protein interaction database STRING (http://string-db.org/) analysis and coimmunoprecipitation assays revealed THBS1 bound to integrin β3. Reduction of integrin β3 levels abrogated the protective effect of THBS1 on vascular calcification. RNA‐seq analysis revealed that THBS1 overexpression modulated the nuclear factor‐kappa B (NF‐κB) signaling pathway. Of note, the inhibitory effect of THBS1 overexpression on the NF‐κB signal was abolished by knockdown of integrin β3. In conclusion, THBS1 interacts with integrin β3 to inhibit vascular calcification through suppression of NF‐κB signal, suggesting a promising therapeutic target for vascular calcification in CKD. © 2025 The Pathological Society of Great Britain and Ireland.
- 10 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 985, 177122
4-Octyl itaconate inhibits vascular calcification partially via modulation of HMOX-1 signaling
- 10 November 2024
- Published by Elsevier in European Journal of Pharmacology
- Vol. 985, 177122
4-Octyl itaconate inhibits vascular calcification partially via modulation of HMOX-1 signaling
- 6 April 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (7) , e23592
Oxidized phospholipid POVPC contributes to vascular calcification by triggering ferroptosis of vascular smooth muscle cells
Vascular calcification is an actively regulated biological process resembling bone formation, and osteogenic differentiation of vascular smooth muscle cells (VSMCs) plays a crucial role in this process. 1‐Palmitoyl‐2‐(5′‐oxo‐valeroyl)‐sn‐glycero‐3‐phosphocholine (POVPC), an oxidized phospholipid, is found in atherosclerotic plaques and has been shown to induce oxidative stress. However, the effects of POVPC on osteogenic differentiation and calcification of VSMCs have yet to be studied. In the present study, we investigated the role of POVPC in vascular calcification using in vitro and ex vivo models. POVPC increased mineralization of VSMCs and arterial rings, as shown by alizarin red staining. In addition, POVPC treatment increased expression of osteogenic markers Runx2 and BMP2, indicating that POVPC promotes osteogenic transition of VSMCs. Moreover, POVPC increased oxidative stress and impaired mitochondria function of VSMCs, as shown by increased ROS levels, impairment of mitochondrial membrane potential, and decreased ATP levels. Notably, ferroptosis triggered by POVPC was confirmed by increased levels of intracellular ROS, lipid ROS, and MDA, which were decreased by ferrostatin‐1, a ferroptosis inhibitor. Furthermore, ferrostatin‐1 attenuated POVPC‐induced calcification of VSMCs. Taken together, our study for the first time demonstrates that POVPC promotes vascular calcification via activation of VSMC ferroptosis. Reducing the levels of POVPC or inhibiting ferroptosis might provide a novel strategy to treat vascular calcification.
- 6 April 2024
- Published by Wiley in The FASEB Journal
- Vol. 38 (7) , e23592
Oxidized phospholipid POVPC contributes to vascular calcification by triggering ferroptosis of vascular smooth muscle cells
Vascular calcification is an actively regulated biological process resembling bone formation, and osteogenic differentiation of vascular smooth muscle cells (VSMCs) plays a crucial role in this process. 1‐Palmitoyl‐2‐(5′‐oxo‐valeroyl)‐sn‐glycero‐3‐phosphocholine (POVPC), an oxidized phospholipid, is found in atherosclerotic plaques and has been shown to induce oxidative stress. However, the effects of POVPC on osteogenic differentiation and calcification of VSMCs have yet to be studied. In the present study, we investigated the role of POVPC in vascular calcification using in vitro and ex vivo models. POVPC increased mineralization of VSMCs and arterial rings, as shown by alizarin red staining. In addition, POVPC treatment increased expression of osteogenic markers Runx2 and BMP2, indicating that POVPC promotes osteogenic transition of VSMCs. Moreover, POVPC increased oxidative stress and impaired mitochondria function of VSMCs, as shown by increased ROS levels, impairment of mitochondrial membrane potential, and decreased ATP levels. Notably, ferroptosis triggered by POVPC was confirmed by increased levels of intracellular ROS, lipid ROS, and MDA, which were decreased by ferrostatin‐1, a ferroptosis inhibitor. Furthermore, ferrostatin‐1 attenuated POVPC‐induced calcification of VSMCs. Taken together, our study for the first time demonstrates that POVPC promotes vascular calcification via activation of VSMC ferroptosis. Reducing the levels of POVPC or inhibiting ferroptosis might provide a novel strategy to treat vascular calcification.